The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Immunotherapy for Neuroblastoma Market 2024 by Company, Regions, Type and Application, Forecast to 2029

Global Immunotherapy for Neuroblastoma Market 2024 by Company, Regions, Type and Application, Forecast to 2029

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1749933

No of Pages : 87

Ask Your Query

Synopsis
The global Immunotherapy for Neuroblastoma market size was valued at USD 46 million in 2022 and is forecast to a readjusted size of USD 63 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

This report is a detailed and comprehensive analysis for global Immunotherapy for Neuroblastoma market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global Immunotherapy for Neuroblastoma market size and forecasts, in consumption value ($ Million), 2018-2029
  • Global Immunotherapy for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
  • Global Immunotherapy for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
  • Global Immunotherapy for Neuroblastoma market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for Immunotherapy for Neuroblastoma
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace

This report profiles key players in the global Immunotherapy for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Immunotherapy for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • Dinutuximab
  • Naxitamab
  • Other

Market segment by Application

  • Hospital
  • Clinic
  • Other

Market segment by players, this report covers

  • United Therapeutics
  • Y-mAbs Therapeutics
  • EUSA Pharma
  • ANI Pharmaceuticals
  • Baxter Healthcare
  • Ingenus Pharmaceuticals
  • Pfizer
  • Hikma Pharmaceuticals
  • Teva Pharmaceuticals

Market segment by regions, regional analysis covers

  • North America (United States, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
  • South America (Brazil, Argentina and Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Immunotherapy for Neuroblastoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Immunotherapy for Neuroblastoma, with revenue, gross margin and global market share of Immunotherapy for Neuroblastoma from 2018 to 2023.
Chapter 3, the Immunotherapy for Neuroblastoma competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Immunotherapy for Neuroblastoma market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Immunotherapy for Neuroblastoma.
Chapter 13, to describe Immunotherapy for Neuroblastoma research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Immunotherapy for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Immunotherapy for Neuroblastoma by Type
1.3.1 Overview: Global Immunotherapy for Neuroblastoma Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Immunotherapy for Neuroblastoma Consumption Value Market Share by Type in 2022
1.3.3 Dinutuximab
1.3.4 Naxitamab
1.3.5 Other
1.4 Global Immunotherapy for Neuroblastoma Market by Application
1.4.1 Overview: Global Immunotherapy for Neuroblastoma Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Immunotherapy for Neuroblastoma Market Size & Forecast
1.6 Global Immunotherapy for Neuroblastoma Market Size and Forecast by Region
1.6.1 Global Immunotherapy for Neuroblastoma Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Immunotherapy for Neuroblastoma Market Size by Region, (2018-2029)
1.6.3 North America Immunotherapy for Neuroblastoma Market Size and Prospect (2018-2029)
1.6.4 Europe Immunotherapy for Neuroblastoma Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Immunotherapy for Neuroblastoma Market Size and Prospect (2018-2029)
1.6.6 South America Immunotherapy for Neuroblastoma Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Immunotherapy for Neuroblastoma Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Immunotherapy for Neuroblastoma Product and Solutions
2.1.4 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 United Therapeutics Recent Developments and Future Plans
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product and Solutions
2.2.4 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Product and Solutions
2.3.4 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 EUSA Pharma Recent Developments and Future Plans
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product and Solutions
2.4.4 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ANI Pharmaceuticals Recent Developments and Future Plans
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Product and Solutions
2.5.4 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Baxter Healthcare Recent Developments and Future Plans
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product and Solutions
2.6.4 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ingenus Pharmaceuticals Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Immunotherapy for Neuroblastoma Product and Solutions
2.7.4 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product and Solutions
2.8.4 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hikma Pharmaceuticals Recent Developments and Future Plans
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product and Solutions
2.9.4 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Teva Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Immunotherapy for Neuroblastoma Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Immunotherapy for Neuroblastoma by Company Revenue
3.2.2 Top 3 Immunotherapy for Neuroblastoma Players Market Share in 2022
3.2.3 Top 6 Immunotherapy for Neuroblastoma Players Market Share in 2022
3.3 Immunotherapy for Neuroblastoma Market: Overall Company Footprint Analysis
3.3.1 Immunotherapy for Neuroblastoma Market: Region Footprint
3.3.2 Immunotherapy for Neuroblastoma Market: Company Product Type Footprint
3.3.3 Immunotherapy for Neuroblastoma Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Immunotherapy for Neuroblastoma Consumption Value and Market Share by Type (2018-2023)
4.2 Global Immunotherapy for Neuroblastoma Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Immunotherapy for Neuroblastoma Consumption Value Market Share by Application (2018-2023)
5.2 Global Immunotherapy for Neuroblastoma Market Forecast by Application (2024-2029)
6 North America
6.1 North America Immunotherapy for Neuroblastoma Consumption Value by Type (2018-2029)
6.2 North America Immunotherapy for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 North America Immunotherapy for Neuroblastoma Market Size by Country
6.3.1 North America Immunotherapy for Neuroblastoma Consumption Value by Country (2018-2029)
6.3.2 United States Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
6.3.3 Canada Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
6.3.4 Mexico Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Immunotherapy for Neuroblastoma Consumption Value by Type (2018-2029)
7.2 Europe Immunotherapy for Neuroblastoma Consumption Value by Application (2018-2029)
7.3 Europe Immunotherapy for Neuroblastoma Market Size by Country
7.3.1 Europe Immunotherapy for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.2 Germany Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
7.3.3 France Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
7.3.5 Russia Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
7.3.6 Italy Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Immunotherapy for Neuroblastoma Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Immunotherapy for Neuroblastoma Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Immunotherapy for Neuroblastoma Market Size by Region
8.3.1 Asia-Pacific Immunotherapy for Neuroblastoma Consumption Value by Region (2018-2029)
8.3.2 China Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
8.3.3 Japan Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
8.3.4 South Korea Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
8.3.5 India Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
8.3.7 Australia Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
9 South America
9.1 South America Immunotherapy for Neuroblastoma Consumption Value by Type (2018-2029)
9.2 South America Immunotherapy for Neuroblastoma Consumption Value by Application (2018-2029)
9.3 South America Immunotherapy for Neuroblastoma Market Size by Country
9.3.1 South America Immunotherapy for Neuroblastoma Consumption Value by Country (2018-2029)
9.3.2 Brazil Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
9.3.3 Argentina Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Immunotherapy for Neuroblastoma Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Immunotherapy for Neuroblastoma Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Country
10.3.1 Middle East & Africa Immunotherapy for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.2 Turkey Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
10.3.4 UAE Immunotherapy for Neuroblastoma Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Immunotherapy for Neuroblastoma Market Drivers
11.2 Immunotherapy for Neuroblastoma Market Restraints
11.3 Immunotherapy for Neuroblastoma Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Immunotherapy for Neuroblastoma Industry Chain
12.2 Immunotherapy for Neuroblastoma Upstream Analysis
12.3 Immunotherapy for Neuroblastoma Midstream Analysis
12.4 Immunotherapy for Neuroblastoma Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock